Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2011-05-09

Clinical Trial Update: Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated adjuvant bevacizumab plus erlotinib for prostate cancer; results were posted after completion in May 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Bevacizumab (bevacizumab)
  • ERLOTINIB (Erlotinib)

Snippet

Sponsor: Translational Oncology Research International | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2011-05-09